Silmitasertib
- Generic Name
- Silmitasertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H12ClN3O2
- CAS Number
- 1009820-21-6
- Unique Ingredient Identifier
- C6RWP0N0L2
- Background
Silmitasertib is under investigation in clinical trial NCT03904862 (Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery).
- Associated Conditions
- -
- Associated Therapies
- -
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- First Posted Date
- 2024-08-07
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 114
- Registration Number
- NCT06541262
- Locations
- 🇺🇸
Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey, Pennsylvania, United States
Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19)
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- University of Arizona
- Target Recruit Count
- 31
- Registration Number
- NCT04668209
- Locations
- 🇺🇸
Banner University Medical Center Phoenix, Phoenix, Arizona, United States
🇺🇸Banner University Medical Center Tucson, Tucson, Arizona, United States
Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Senhwa Biosciences, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04663737
- Locations
- 🇺🇸
Center for Advanced Research and Education, Gainesville, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath